UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT of 1934

 

For the Month of June 2017

 

001-37521

(Commission File Number)

 

INTEC PHARMA LTD.

(Translation of registrant’s name into English)

 

12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel

(+972) (2) 586-4657

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________

 

 

 

 

EXPLANATORY NOTE

 

On May 31, 2017, Intec Pharma Ltd., issued a press release titled “Intec Pharma to Participate at Upcoming June Conferences.”

 

Copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference hereto.

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  INTEC PHARMA LTD.
     
  By: /s/ Giora Carni
    Name: Giora Carni
    Title: Chief Executive Officer
     
Date: June 1, 2017    

 

 3 

 

  

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Press Release, dated May 31, 2017

 

 4 

 

Exhibit 99.1

 

 

 

Intec Pharma to Participate at Upcoming June Conferences

 

JERUSALEM (May 31, 2017) – Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion PillTM platform technology, announces that the company will participate at the following two upcoming June conferences:

 

LD Micro Invitational

Date and Time: Tuesday, June 6, 2017, 8:00 a.m. Pacific Time
Venue: Luxe Sunset Boulevard Hotel, Los Angeles, CA
Format: Company presentation
Presenter: John Kozarich, Ph.D., Chairman of the Board

 

Jefferies 2017 Global Healthcare Conference

Date and Time: Friday, June 9, 2017, 9:00 a.m. Eastern Time
Venue: Grand Hyatt, New York, NY
Format: Company presentation
Presenter: Jeffrey Meckler, Vice Chairman

 

Dr. Kozarichs and Mr. Mecklers presentations will be webcast live and can be accessed on the Investor Relations section of the Companys website at www.intecpharma.com where they will be archived for a period of time.

 

About Intec Pharma Ltd.

 

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, or AP-ZP, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug (NSAID)-induced ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

 

 

 

 

Contacts:

John Kozarich, Ph.D.

Chairman of the Board

Intec Pharma

john@intecpharma.com

 

Anne Marie Fields

Senior Vice President

LHA Investor Relations

212-838-3777

afields@lhai.com

 

# # #